The DOI matches its Crossref record.
Liposomal amphotericin B (AmBisome): safety data from a phase II/III clinical trial
Abstract
AmBisome is a commercially available preparation of amphotericin B incorporated in small unilamellar liposomes. The analysis of safety data provided in a multicentre compassionate phase II/III study evaluating 133 episodes of therapy with AmBisome in patients with severe underlying disease is very encouraging. Rapid (30-60 min) administration of a high daily dose of AmBisome is feasible without the well known side effects observed with the conventional formulation of amphotericin B (Fungizone). Although eleven of 71 patients with initially normal serum creatinine concentrations showed increased values after AmBisome therapy, 17 patients among 50 with initially high creatinine concentrations recovered normal renal function during AmBisome treatment. Hypokalaemia was observed in 24 episodes of treatment (18%). Increases in serum glutamyl oxaloacetic transaminase and alkaline phosphatase were also quite common in this selected population with severe underlying disease and the contribution of AmBisome to these changes is difficult to establish. AmBisome appears a safe alternative to conventional amphotericin B, and its efficacy should be further investigated.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
New developments in liposomal drug delivery
Pattni, B. S., Chupin, V. V., & Torchilin, V. P. (2015) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00046 · Cited by 1,600
Sapsford, K. E., Algar, W. R., Berti, L., Gemmill, K. B., Casey, B. J., Oh, E., Stewart, M. H., & Medintz, I. L. (2013) · Chemical Reviews · doi:10.1021/cr300143v · Cited by 1,423
Liposomal Amphotericin B for Empirical Therapy in Patients with Persistent Fever and Neutropenia
Walsh, T. J., Finberg, R. W., Arndt, C., Hiemenz, J., Schwartz, C., Bodensteiner, D., Pappas, P., Seibel, N., Greenberg, R. N., Dummer, S., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199903113401004 · Cited by 1,205
Lipid-Based Nanoparticles as Pharmaceutical Drug Carriers: From Concepts to Clinic
Puri, A., Loomis, K., Smith, B., Lee, J.-H., Yavlovich, A., Heldman, E., & Blumenthal, R. (2009) · Critical Reviews in Therapeutic Drug Carrier Systems · doi:10.1615/critrevtherdrugcarriersyst.v26.i6.10 · Cited by 1,069
Yeh, M.-K., Chang, H.-I., & Cheng, M.-Y. (2011) · International Journal of Nanomedicine · doi:10.2147/ijn.s26766 · Cited by 801
Clinical Translation of Nanomedicine
Min, Y., Caster, J. M., Eblan, M. J., & Wang, A. Z. (2015) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00116 · Cited by 772
Foulkes, R., Man, E., Thind, J., Yeung, S., Joy, A., & Hoskins, C. (2020) · Biomaterials Science · doi:10.1039/d0bm00558d · Cited by 568
Szebeni, J. (2014) · Molecular Immunology · doi:10.1016/j.molimm.2014.06.038 · Cited by 457
Liposomes in Drug Delivery: Clinical, Diagnostic and Ophthalmic Potential
Gregoriadis, G., & Florence, A. T. (1993) · Drugs · doi:10.2165/00003495-199345010-00003 · Cited by 452
Lipid Formulations of Amphotericin B: Recent Progress and Future Directions
Hiemenz, J. W., & Walsh, T. J. (1996) · Clinical Infectious Diseases · doi:10.1093/clinids/22.supplement_2.s133 · Cited by 404
Walsh, T. J., Goodman, J. L., Pappas, P., Bekersky, I., Buell, D. N., Roden, M., Barrett, J., & Anaissie, E. J. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.12.3487-3496.2001 · Cited by 401
Lipid Formulations of Amphotericin B: Clinical Efficacy and Toxicities
Wong-Beringer, A., Jacobs, R. A., & Guglielmo, B. J. (1998) · Clinical Infectious Diseases · doi:10.1086/514704 · Cited by 395
Nanocarrier-based systems for targeted and site specific therapeutic delivery
Majumder, J., Taratula, O., & Minko, T. (2019) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2019.07.010 · Cited by 394
Cavassin, F. B., Baú-Carneiro, J. L., Vilas-Boas, R. R., & Queiroz-Telles, F. (2021) · Infectious Diseases and Therapy · doi:10.1007/s40121-020-00382-7 · Cited by 382
Groll, A. H., Piscitelli, S. C., & Walsh, T. J. (1998) · Advances in pharmacology · doi:10.1016/s1054-3589(08)60129-5 · Cited by 377
Invasive Aspergillosis: Epidemiology, Diagnosis and Management in Immunocompromised Patients
Maschmeyer, G., Haas, A., & Cornely, O. A. (2007) · Drugs · doi:10.2165/00003495-200767110-00004 · Cited by 366
It only takes one to do many jobs: Amphotericin B as antifungal and immunomodulatory drug
Mesa-Arango, A. C., Scorzoni, L., & Zaragoza, O. (2012) · Frontiers in Microbiology · doi:10.3389/fmicb.2012.00286 · Cited by 311
“Unfortunately, this formulation is highly nephrotoxic and shows side effects as fevers, malaise, weight loss, headache, hypotension, abdominal pain, nausea, vomiting, diarrhea, normochromic normocytic anemia, and myalgia (Sabra and Branch, 1990; Meunier et al., 1991; Ringden et al., 1991; Gulati et al., 1998; LaniadoL…”
BackgroundLemke, A., Kiderlen, A. F., & Kayser, O. (2005) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-005-1955-9 · Cited by 305
Amphotericin B Formulations and Drug Targeting
Torrado, J. J., Espada, R., Ballesteros, M. P., & Torrado-Santiago, S. (2008) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21179 · Cited by 299
Sustained-release from nanocarriers: a review
Natarajan, J. V., Nugraha, C., Ng, X. W., & Venkatraman, S. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.05.029 · Cited by 285
Liposomal and Lipid Formulations of Amphotericin B: Clinical Pharmacokinetics
Janknegt, R., de Marie, S., Bakker-Woudenberg, I. A. J. M., & Crommelin, D. J. A. (1992) · Clinical Pharmacokinetics · doi:10.2165/00003088-199223040-00004 · Cited by 274
Mesa-Arango, A. C., Trevijano-Contador, N., Román, E., Sánchez-Fresneda, R., Casas, C., Herrero, E., Argüelles, J. C., Pla, J., Cuenca-Estrella, M., & Zaragoza, O. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.03570-14 · Cited by 232
Liposomal amphotericin B treatment for neonatal fungal infections
SCARCELLA, A., PASQUARIELLO, M. B., GIUGLIANO, B., VENDEMMIA, M., & DE LUCIA, A. (1998) · The Pediatric Infectious Disease Journal · doi:10.1097/00006454-199802000-00013 · Cited by 135
Metadata
- Authors
- Meunier, F., Prentice, H. G., & Ringden, O.
- Venue
- Journal of Antimicrobial Chemotherapy
- Publisher
- Oxford University Press (OUP)
- Published
- 1991-01-01
- Volume
- 28
- Issue
- suppl B
- Pages
- 83-91
- ISSN
- 0305-7453 (ISSN-L)
- 1460-2091
- OpenAlex
- W2005581514
- Cited by
- 247
- References
- 0
- FWCI
- 13.24
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.